Cytokinetics to Present at the 16th Annual Needham Healthcare Conference
March 29 2017 - 4:00PM
Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I.
Blum, President and Chief Executive Officer, is scheduled to
present a corporate update at the 16th Annual Needham Healthcare
Conference on Wednesday, April 5, 2017 at 10:40 AM ET at the Westin
Grand Central Hotel in New York.
Interested parties may access the live webcast
of this presentation by visiting the Investors & Media section
of the Cytokinetics website at www.cytokinetics.com. The webcast
replay of the presentation will be archived on the Presentations
page within the Investors & Media section of Cytokinetics'
website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators as potential treatments for
debilitating diseases in which muscle performance is compromised
and/or declining. As a leader in muscle biology and the mechanics
of muscle performance, the company is developing small molecule
drug candidates specifically engineered to increase muscle function
and contractility. Cytokinetics’ lead drug candidate is tirasemtiv,
a fast skeletal troponin activator (FSTA). Tirasemtiv is the
subject of VITALITY-ALS, an international Phase 3 clinical trial in
patients with ALS. Tirasemtiv has been granted orphan drug
designation and fast track status by the U.S. Food and Drug
Administration and orphan medicinal product designation by the
European Medicines Agency. Cytokinetics is preparing for the
potential commercialization of tirasemtiv in North America and
Europe and has granted an option to Astellas for development and
commercialization in other countries. Cytokinetics is collaborating
with Astellas to develop CK-2127107, a next-generation fast
skeletal muscle activator. CK-2127107 is the subject of two ongoing
Phase 2 clinical trials enrolling patients with spinal muscular
atrophy and chronic obstructive pulmonary disease. Cytokinetics is
collaborating with Amgen Inc. to develop omecamtiv mecarbil, a
novel cardiac muscle activator. Omecamtiv mecarbil is the subject
of GALACTIC-HF, an international Phase 3 clinical trial in patients
with heart failure. Amgen holds an exclusive worldwide license to
develop and commercialize omecamtiv mecarbil with a sublicense held
by Servier for commercialization in Europe and certain other
countries. Astellas holds an exclusive worldwide license to develop
and commercialize CK-2127107. Licenses held by Amgen and Astellas
are subject to Cytokinetics' specified co-development and
co-commercialization rights. For additional information about
Cytokinetics, visit http://www.cytokinetics.com/.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Act’s safe harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to planned
presentations, and the properties and potential benefits of
Cytokinetics’ drug candidates and potential drug candidates. Such
statements are based on management’s current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to, potential
difficulties or delays in the development, testing, regulatory
approval and production of Cytokinetics' drug candidates
and potential drug candidates that could slow or prevent clinical
development or product approval, including risks that current and
past results of clinical trials or preclinical studies may not be
indicative of future clinical trials results and
that Cytokinetics' drug candidates and potential drug
candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and
other risks related to Cytokinetics’ business, investors should
consult Cytokinetics’ filings with the Securities and Exchange
Commission.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024